A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The main aim of the study is to evaluate the efficacy and safety of lebrikizumab treatment for up to 32 weeks in participants with moderate-to-severe face and neck atopic dermatitis (FNAD) who also have moderate-to-severe AD outside of the face and neck region, and who are in need of systemic therapy.
Epistemonikos ID: 20f55df6a1283a11e0bb5a650db70484b57c7b96
First added on: Oct 15, 2026